FDA Signs Onto EMA Analysis Of Incretin Mimetics; Labeling For Diabetes Drugs Is Adequate
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA finds no new concerns of pancreatic risks of GLP-1 based diabetes drugs, says worrisome study of tissue samples from organ donors has limitations.